Wall Street brokerages expect that Mediwound Ltd (NASDAQ:MDWD) will post $690,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Mediwound’s earnings. The lowest sales estimate is $660,000.00 and the highest is $700,000.00. Mediwound posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 60.5%. The company is expected to issue its next earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Mediwound will report full-year sales of $690,000.00 for the current fiscal year, with estimates ranging from $2.53 million to $2.63 million. For the next year, analysts anticipate that the company will post sales of $8.35 million per share, with estimates ranging from $5.80 million to $9.83 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Mediwound.

Several equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. Zacks Investment Research lowered shares of Mediwound from a “buy” rating to a “hold” rating in a research note on Tuesday, November 21st. SunTrust Banks set a $9.00 target price on shares of Mediwound and gave the stock a “buy” rating in a research note on Thursday, November 16th. Oppenheimer set a $10.00 target price on shares of Mediwound and gave the stock a “buy” rating in a research note on Thursday, November 16th. Finally, Cowen initiated coverage on shares of Mediwound in a research note on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $9.13.

Shares of Mediwound (NASDAQ:MDWD) opened at $4.95 on Friday. Mediwound has a 12 month low of $4.15 and a 12 month high of $8.25.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. acquired a new stake in Mediwound in the 3rd quarter valued at about $2,140,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Mediwound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after acquiring an additional 342,165 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in Mediwound in the 3rd quarter valued at about $1,538,000. Wells Fargo & Company MN raised its holdings in Mediwound by 23.5% in the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 12,522 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Mediwound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 29.46% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/02/690000-00-in-sales-expected-for-mediwound-ltd-mdwd-this-quarter.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.